Acorda Buys Its Way Into A Parkinson's Franchise
This article was originally published in The Pink Sheet Daily
Having acquired Parkinson's candidate CVT-301 in the 2014 purchase of Civitas, Acorda sees Biotie's Phase III tozadenant as an ideal candidate to create a complementary Parkinson's disease franchise.
You may also be interested in...
Sumitomo Dainippon unit pays a 123% premium to acquire Cynapsus and its Phase III Parkinson's drug APL-130277, with at least one analyst speculating it paid a high price in order to avoid a bidding war.
Company says it will not pursue regulatory filings for the adenosine-2a receptor antagonist because studies in moderate-to-severe and early-stage disease failed to show sufficient evidence of efficacy.
BVMed says the EU and the UK should set up a system of mutual recognition of medical device regulation to kick in when the UK’s EU exit transition period ends on 31 December.